SOURCES & STANDARDS
Where our
stem cells
come from
Not all stem cells carry the same therapeutic potential. Their origin, donor characteristics, and manufacturing process determine everything. We explain ours in full.
Three source categories.
One choice.
Stem cells exist across multiple biological origins, each with different properties, risks, and clinical evidence. Understanding the landscape clarifies why source selection matters.
OMNISTEM’S SOURCE
Perinatal Birth-Associated Tissues
Donor age Neonatal — maximally youthful cell phenotype
Invasiveness None — collected post-birth with full ethical consent
Immunogenicity Low — allogeneic use without HLA matching typically tolerated
Evidence tier Peer-reviewed, clinical trials across multiple conditions
REFERENCE CATEGORY
Autologous
Invasiveness Moderate to high (bone marrow aspiration, liposuction)
Rejection risk None, but lower proliferative capacity in older donors
NOT USED AT OMNISTEM
Pluripotent
ESC · iPSC
Embryonic stem cells and induced pluripotent cells can form virtually any cell type, but carry significant risks, including tumor formation (teratoma), and face major regulatory and ethical constraints internationally.
Tumor risk Present — teratoma risk not yet clinically resolved
Why Wharton's Jelly UC-MSCs
The umbilical cord’s gelatinous connective tissue, Wharton’s Jelly, contains one of the most therapeutically potent populations of mesenchymal stem cells currently available for clinical use.
Ethical Donation
Umbilical cords are donated by healthy mothers following full-term, uncomplicated births. Written informed consent is obtained prior to delivery. No embryonic material is used.
Donor Screening
All donors undergo comprehensive infectious disease testing, genetic screening, and metabolic profiling prior to cord processing. Only donors who meet full criteria proceed.
Wharton's Jelly Isolation
The gelatinous connective tissue is carefully separated from cord vasculature. MSCs are isolated under GMP-aligned conditions and characterized for surface markers (CD73, CD90, CD105 positive; CD34, CD45 negative).
Expansion & Quality Control
Cells are expanded under controlled laboratory conditions. Each batch undergoes triple certification: sterility, viability (>90%), and identity verification before release.
Cryopreservation & Administration
Final product is cryopreserved and thawed immediately prior to infusion. Full donor-to-patient traceability is maintained throughout the chain of custody.
Stem Cell Sources Compared
Not all stem cells offer the same regenerative potential. Here is how the primary sources compare across clinical and ethical criteria.
| Criteria | UC-MSC (Umbilical Cord) | Bone Marrow (BM-MSC) | Adipose (AD-MSC) | Embryonic (ESC) |
|---|---|---|---|---|
| Source Tissue | Wharton's Jelly from umbilical cord | Iliac crest aspiration (hip bone) | Liposuction / fat tissue | Pre-implantation embryo |
| Donor Age Impact | ✓ Neonatal — youngest cellular age | ● Declines with donor age | ● Declines with donor age | ✓ Very young |
| Proliferative Capacity | ✓ High | ● Moderate, age-dependent | ● Moderate | ✓ Very high |
| Immunogenicity | ✓ Low — well-tolerated | ● Moderate | ● Moderate | ● High rejection risk |
| Anti-inflammatory Potency | ✓ Superior cytokine modulation | ● Established but limited | ● Variable | ● Not primary use |
| Collection Invasiveness | ✓ Non-invasive — postpartum | ● Surgical aspiration | ● Liposuction required | ● Embryo destruction |
| Ethical Status | ✓ No ethical controversy | ✓ No controversy | ✓ No controversy | ● Significant debate |
| Availability | ✓ Allogeneic — readily available | ● Autologous — patient-specific | ● Autologous — patient-specific | ● Highly restricted |
The same source standard. Smaller scale.
OmniStem’s exosomes are derived exclusively from UC-MSC cultures, the same Wharton’s Jelly MSCs used in our cell-based protocols. Source consistency is non-negotiable.
OMNISTEM ONLY
UC-MSC Derived Exosomes
Delivery IV infusion, nebulization, local injections.
Cargo miRNAs, growth factors, cytokines, proteins, lipids, and other bioactive molecules.
NOT USED AT OMNISTEM
Other Exosome Sources
Cosmetic Plant-derived “exosomes” are not human EVs
No embryonic material. Ever.
OmniStem does not use embryonic stem cells, undifferentiated iPSCs, or any source that raises ethical or tumor-formation concerns.
Full chain-of-custody traceability
Every product is tracked from donor consent through batch release to patient administration under Ministry of Health oversight.
Produced in-house, GMP-aligned
No outsourcing. OmniStem Lab processes, characterizes, and releases all biologics internally, complete quality control, no intermediary supply chain.
Frequently Asked Questions
Your case.
In our hands.
Within 48 hours.
A physician on the OmniStem medical team will review your clinical profile and prepare an initial assessment. What follows is a medical conversation.
Your clinical profile 2 MIN
A brief summary of your health context. The medical team uses this to prepare before your first conversation.
Physician review 48 H
Dr. Montoya or a member of the medical team evaluates your profile individually.
A clinical conversation
Your history, your priorities, and what a protocol designed around your clinical profile might include.
No obligation
The case review is informational. The only timeline that matters is yours.
Step 1
A few questions to begin
These help the medical team understand whether OmniStem’s protocols are appropriate for your situation before we speak.